SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Pablo Neruda Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPablo Neruda
Date of birth1904-07-12
IdentifiersMRN HR-ML051-SYN-TD; SSN (made up) 000-51-2976
Document date2026-11-01
AuthorMarisol Fairweather-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral. Concerns: He wants to know what the pain and the urinary symptoms mean, and to be told plainly; He wants to keep writing every morning and to carry on his duties as ambassador; He wants important discussions held in Spanish. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route1966-04-06 to 1971-07-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1971-07-13activeS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone painTwo tablets up to three times daily as neededOral route1971-06-01 to 1971-09-14completedS
Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without foodOne tablet once dailyOral route1971-06-15activeS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeksOne injection every twelve weeksIntramuscular route1971-06-22activeS
Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet dailyOne tablet dailyOral route1971-06-15activeS
Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivationOne injection every six monthsSubcutaneous route1971-07-13activeS
Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin)Twice daily for two weeksTopical route1971-08-10 to 1971-08-24completedS
Cetirizine 10 mg oral tablet, one tablet daily for itchOne tablet dailyOral route1971-08-10 to 1971-08-31completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1971-10-05activeS

Procedures

ProcedureDatesStatusEvidence
Multiparametric MRI of the prostate: gland 52 mL; 24 mm PI-RADS 5 lesion in the right peripheral zone from mid-gland to base with extraprostatic extension on the right; no seminal vesicle invasion; 13 mm right external iliac lymph node; abnormal marrow signal in the right iliac bone at the edge of the field1971-06-03 to 1971-06-03completedS
CT of the chest, abdomen and pelvis with contrast: enlarged right external iliac (13 mm) and right obturator (11 mm) lymph nodes; sclerotic lesions in the right iliac wing and the L5 vertebral body without a soft-tissue mass or canal narrowing; no lung, liver or adrenal lesions1971-06-04 to 1971-06-04completedS
Whole-body bone scan (technetium-99m): two foci of increased uptake, in the right iliac wing and L5, matching the CT; no other skeletal lesions (fewer than four bone metastases, all in the spine and pelvis: low volume)1971-06-04 to 1971-06-04completedS
MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+4 (Grade Group 4) in 3 of 3 targeted cores (up to 80 percent of the core) and Gleason 4+4 or 4+3 in 6 of 12 systematic cores, all on the right; 9 of 14 cores in all; perineural invasion present; no intraductal or neuroendocrine features1971-06-08 to 1971-06-08completedS
Gallium-68 PSMA PET/CT: intense uptake in the right side of the prostate, in the right external iliac and right obturator nodes, and in the right iliac wing and L5; no other nodal, bone or visceral disease1971-06-11 to 1971-06-11completedS
Bone densitometry (DXA) of the hip and lumbar spine before androgen deprivation; L5 excluded because of a metastasis1971-06-15 to 1971-06-15completedS
Image-guided intensity-modulated radiotherapy to the prostate, 55 Gy in 20 daily fractions over four weeks, for low-volume metastatic disease; no pelvic nodal or bone radiation1971-07-27 to 1971-08-21completedS
Advance care planning conversation, about 30 minutes, in Spanish with a professional interpreter, with his consent1971-10-05 to 1971-10-05completedS

Immunizations

DateVaccineStatusEvidence
1965-09-21Tdap vaccinecompletedS
1970-10-14High-dose influenza vaccine, last seasoncompletedS
1971-10-05High-dose influenza vaccine, this seasoncompletedS
1971-10-05COVID-19 vaccine, mRNA, this seasoncompletedS
1971-10-05Pneumococcal conjugate vaccine PCV20completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

RelativeConditionAge at deathEvidence
motherDied shortly after his birth; cause not recorded in the cited sourceD (CLM-0001)

Health Concerns

ConcernStatusEvidence
He wants to know what the pain and the urinary symptoms mean, and to be told plainlyactiveS
He wants to keep writing every morning and to carry on his duties as ambassadoractiveS
He wants important discussions held in SpanishactiveS

Assessment

Most recent measures: Prostate specific Ag [Mass/volume] in Serum or Plasma 0.18 on 1971-09-14; Testosterone [Mass/volume] in Serum or Plasma 14 on 1971-09-14; Hemoglobin [Mass/volume] in Blood 12.9 on 1971-09-14; Leukocytes [#/volume] in Blood by Automated count 5.9 on 1971-09-14; Platelets [#/volume] in Blood by Automated count 231 on 1971-09-14; Sodium [Moles/volume] in Serum or Plasma 140 on 1971-09-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 1971-09-14; Glucose [Mass/volume] in Serum or Plasma 102 on 1971-09-14; Creatinine [Mass/volume] in Serum or Plasma 0.99 on 1971-09-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 83 on 1971-09-14; Calcium [Mass/volume] in Serum or Plasma 9.2 on 1971-09-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1971-09-14; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1971-09-14; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 96 on 1971-09-14; Albumin [Mass/volume] in Serum or Plasma 4 on 1971-09-14; Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma 208 on 1971-06-01; Hemoglobin A1c/Hemoglobin.total in Blood 6.1 on 1971-09-14; Cholesterol [Mass/volume] in Serum or Plasma 214 on 1971-06-01; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 1971-06-01; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 140 on 1971-06-01; Triglyceride [Mass/volume] in Serum or Plasma 140 on 1971-06-01; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 28 on 1971-07-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1971-06-01; International Prostate Symptom Score [IPSS] 9 on 1971-09-14; Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 on 1971-09-14; DXA Femur [T-score] Bone density -2.1 on 1971-06-15; DXA Lumbar spine [T-score] Bone density -1.4 on 1971-06-15; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1971-10-05; Thyrotropin [Units/volume] in Serum or Plasma 5.4 on 1971-09-14; Eosinophils [#/volume] in Blood by Automated count 0.3 on 1971-08-10; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 on 1971-09-14; Total score [Mini-Cog] 5 on 1971-10-05; Total score [AUDIT-C] 2 on 1971-10-05 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmedresolvedconfirmed R97.20S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.
Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916activeconfirmed C61S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.
Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites.
Pelvic lymph node metastases: right external iliac and right obturator nodesactiveconfirmed C77.5S — Synthetic nodal disease.
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognitionactiveconfirmed Z79.899S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
Essential hypertension for five years, on amlodipineactiveconfirmed I10S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding at intake, addressed at the second visit.
Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)activeconfirmed M85.89S — Synthetic bone-health finding on the DXA before androgen deprivation.
Prediabetes (hemoglobin A1c 5.9%)activeconfirmed R73.03S — Synthetic metabolic finding at intake, relevant to androgen deprivation.
Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamideresolvedconfirmed L27.0S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim.
Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit)activeconfirmed Z92.3S — Synthetic: recorded after the course of radiotherapy finished.
Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observationactiveconfirmed R94.6S — Synthetic finding; raised TSH is a known effect of apalutamide.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1971-06-01Prostate specific Ag [Mass/volume] in Serum or Plasma46.8ng/mL<=4 ng/mLHighS
1971-06-01Testosterone [Mass/volume] in Serum or Plasma468ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationNormalS
1971-06-01Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
1971-06-01Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
1971-06-01Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
1971-06-01Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1971-06-01Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1971-06-01Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
1971-06-01Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.74-1.35 mg/dLNormalS
1971-06-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1971-06-01Calcium [Mass/volume] in Serum or Plasma9.6mg/dL8.6-10.3 mg/dLNormalS
1971-06-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-55 U/LNormalS
1971-06-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-48 U/LNormalS
1971-06-01Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma168U/L40-129 U/LHighS
1971-06-01Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
1971-06-01Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma208U/L135-225 U/LNormalS
1971-06-01Hemoglobin A1c/Hemoglobin.total in Blood5.9%<=5.6%HighS
1971-06-01Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
1971-06-01Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
1971-06-01Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation140mg/dL<=129 mg/dLHighS
1971-06-01Triglyceride [Mass/volume] in Serum or Plasma140mg/dL<=149 mg/dLNormalS
1971-06-0125-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma22ng/mL30-100 ng/mLLowS
1971-06-01Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1971-06-01International Prostate Symptom Score [IPSS]17{score}S
1971-06-01Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S
1971-06-15DXA Femur [T-score] Bone density-2.1{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
1971-06-15DXA Lumbar spine [T-score] Bone density-1.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
1971-06-15Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1971-06-15Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S
1971-07-13Prostate specific Ag [Mass/volume] in Serum or Plasma6.2ng/mL<=4 ng/mLHighS
1971-07-13Testosterone [Mass/volume] in Serum or Plasma22ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
1971-07-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1971-07-13Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1971-07-13Glucose [Mass/volume] in Serum or Plasma101mg/dL70-99 mg/dLHighS
1971-07-13Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.74-1.35 mg/dLNormalS
1971-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1971-07-13Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1971-07-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L7-55 U/LNormalS
1971-07-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L8-48 U/LNormalS
1971-07-13Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma141U/L40-129 U/LHighS
1971-07-13Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
1971-07-1325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma28ng/mL30-100 ng/mLLowS
1971-07-13Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.45-4.5 mIU/LNormalS
1971-07-13Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1971-07-13International Prostate Symptom Score [IPSS]14{score}S
1971-07-13Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
1971-08-10Leukocytes [#/volume] in Blood by Automated count6.810*3/uL4-11 10*3/uLNormalS
1971-08-10Eosinophils [#/volume] in Blood by Automated count0.310*3/uL0-0.5 10*3/uLNormalS
1971-08-10Creatinine [Mass/volume] in Serum or Plasma0.97mg/dL0.74-1.35 mg/dLNormalS
1971-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M86mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1971-08-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-55 U/LNormalS
1971-08-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-48 U/LNormalS
1971-09-14Prostate specific Ag [Mass/volume] in Serum or Plasma0.18ng/mL<=4 ng/mLNormalS
1971-09-14Testosterone [Mass/volume] in Serum or Plasma14ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
1971-09-14Hemoglobin [Mass/volume] in Blood12.9g/dL13.2-16.6 g/dLLowS
1971-09-14Leukocytes [#/volume] in Blood by Automated count5.910*3/uL4-11 10*3/uLNormalS
1971-09-14Platelets [#/volume] in Blood by Automated count23110*3/uL150-400 10*3/uLNormalS
1971-09-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1971-09-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1971-09-14Glucose [Mass/volume] in Serum or Plasma102mg/dL70-99 mg/dLHighS
1971-09-14Creatinine [Mass/volume] in Serum or Plasma0.99mg/dL0.74-1.35 mg/dLNormalS
1971-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1971-09-14Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
1971-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
1971-09-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
1971-09-14Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma96U/L40-129 U/LNormalS
1971-09-14Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1971-09-14Thyrotropin [Units/volume] in Serum or Plasma5.4m[IU]/L0.45-4.5 mIU/LHighS
1971-09-14Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
1971-09-14Hemoglobin A1c/Hemoglobin.total in Blood6.1%<=5.6%HighS
1971-09-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1971-09-14International Prostate Symptom Score [IPSS]9{score}S
1971-09-14Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S
1971-10-05Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1971-10-05Total score [Mini-Cog]5{score}S
1971-10-05Total score [AUDIT-C]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1971-06-01Body height178cmS
1971-06-01Body weight92.4kgS
1971-06-01Body mass index (BMI) [Ratio]29.2kg/m2S
1971-06-01Systolic blood pressure146mm[Hg]S
1971-06-01Diastolic blood pressure88mm[Hg]S
1971-06-01Heart rate76/minS
1971-06-01Respiratory rate14/minS
1971-06-01Body temperature36.7CelS
1971-06-01Oxygen saturation in Arterial blood by Pulse oximetry97%S
1971-06-15Body height178cmS
1971-06-15Body weight92kgS
1971-06-15Body mass index (BMI) [Ratio]29kg/m2S
1971-06-15Systolic blood pressure142mm[Hg]S
1971-06-15Diastolic blood pressure86mm[Hg]S
1971-06-15Heart rate74/minS
1971-06-15Respiratory rate14/minS
1971-06-15Body temperature36.6CelS
1971-06-15Oxygen saturation in Arterial blood by Pulse oximetry97%S
1971-07-13Body height178cmS
1971-07-13Body weight92.8kgS
1971-07-13Body mass index (BMI) [Ratio]29.3kg/m2S
1971-07-13Systolic blood pressure152mm[Hg]S
1971-07-13Diastolic blood pressure90mm[Hg]S
1971-07-13Heart rate76/minS
1971-07-13Respiratory rate14/minS
1971-07-13Body temperature36.6CelS
1971-07-13Oxygen saturation in Arterial blood by Pulse oximetry97%S
1971-08-10Body height178cmS
1971-08-10Body weight93kgS
1971-08-10Body mass index (BMI) [Ratio]29.4kg/m2S
1971-08-10Systolic blood pressure136mm[Hg]S
1971-08-10Diastolic blood pressure82mm[Hg]S
1971-08-10Heart rate80/minS
1971-08-10Respiratory rate14/minS
1971-08-10Body temperature36.8CelS
1971-08-10Oxygen saturation in Arterial blood by Pulse oximetry97%S
1971-09-14Body height178cmS
1971-09-14Body weight94.2kgS
1971-09-14Body mass index (BMI) [Ratio]29.7kg/m2S
1971-09-14Systolic blood pressure132mm[Hg]S
1971-09-14Diastolic blood pressure80mm[Hg]S
1971-09-14Heart rate72/minS
1971-09-14Respiratory rate14/minS
1971-09-14Body temperature36.6CelS
1971-09-14Oxygen saturation in Arterial blood by Pulse oximetry97%S
1971-10-05Body height178cmS
1971-10-05Body weight94.6kgS
1971-10-05Body mass index (BMI) [Ratio]29.9kg/m2S
1971-10-05Systolic blood pressure128mm[Hg]S
1971-10-05Diastolic blood pressure78mm[Hg]S
1971-10-05Heart rate70/minS
1971-10-05Respiratory rate14/minS
1971-10-05Body temperature36.6CelS
1971-10-05Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1971-06-01New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referralfinishedS
1971-06-15Two-week review with the medical oncology consultation the same day: biopsy and staging results, the diagnosis, shared decision on treatment, the start of apalutamide, genetic testing, and bone densityfinishedS
1971-07-13Four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy planfinishedS
1971-09-14Three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the yearfinishedS
1971-08-10Same-day sick visit for an itchy rash on apalutamidefinishedS
1971-10-05Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testingcompletedGL-NCCN-PROSTATE-2026, GL-AUA-APC-2026S
Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CTcompletedGL-NCCN-PROSTATE-2026, GL-AUA-APC-2026, GL-CMID-2026S
Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel controlcompletedGL-NCCN-PROSTATE-2026S
Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official dutiescompletedGL-NCCN-PROSTATE-2026S
Systemic therapy: apalutamide 240 mg daily from the consultation day and leuprolide 22.5 mg every twelve weeks from one week later, continuous; docetaxel not added for low-volume diseasecompletedGL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-TITAN-2019, GL-CHAARTED-2018S
Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation, for low-volume metastatic diseasecompletedGL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-STAMPEDE-H-2018S
Germline genetic testing with pre-test counseling, and somatic testing of the biopsy tissuecompletedGL-AUA-APC-2026, GL-NCCN-PROSTATE-2026S
Bone health on androgen deprivation: DXA and FRAX, cholecalciferol 1945 units a day, calcium 1000 to 1200 mg a day from food, weight-bearing exercise, a dental examination, then denosumab 60 mg every six months for high fracture risk; DXA again in one to two yearscompletedGL-AUA-APC-2026, GL-CMID-2026, GL-CALGB90202-2014S
Monitoring on androgen deprivation and apalutamide: PSA and testosterone every three months, blood count and chemistry, TSH every four months, blood pressure at every visit, hemoglobin A1c and lipids, rash, falls, hot flashes, sexual health, fatigue, mood and cognitioncompletedGL-CMID-2026, GL-ERLEADA-2026, GL-AUA-APC-2026S
Apalutamide rash: triamcinolone 0.1% cream twice daily for two weeks, cetirizine 10 mg daily, fragrance-free emollient, continue apalutamide; stop it and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skincompletedGL-ERLEADA-2026, GL-NCCN-PROSTATE-2026S
Atorvastatin 20 mg daily for primary prevention, with a lipid panel and ALT in six to twelve weekscompletedGL-USPSTF-STATIN-2022, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Diagnosis, staging and a shared treatment decision within three weeks of the first visit1971-06-15completedBiopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intakeS
Bone pain controlled, with a pain score of 2 or less and sleep restored1971-07-13completedPain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivationS
PSA of 0.2 ng/mL or less within about seven months of starting treatment1971-09-14completedPSA 46.8 to 0.18 ng/mL at three monthsS
Blood pressure below 130/80 mm Hg on androgen deprivation1971-10-05completed152/90 at four weeks on apalutamide; 128/78 at the annual wellness visit on amlodipine 10 mgS
Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk1971-10-05activeDenosumab given at four weeks after a dental check; vitamin D 28 ng/mL and rising; walking dailyS
Keep his morning writing and his official duties through treatment1971-10-05completedWriting every morning; one week of official engagements postponed during radiotherapyS

Functional Status

Mental Status